Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study

There are no real-life studies comparing the efficacy and safety of the different antitumor necrosis factor (TNF)-α drugs available in patients with ulcerative colitis (UC) and Crohn's disease (CD). To verify the effectiveness and tolerability of different anti–TNF-α agents (infliximab [IFX] or...

Descripción completa

Detalles Bibliográficos
Autores principales: Barberio, Brigida, Zingone, Fabiana, D'Incà, Renata, Rovigo, Laura, Bertani, Lorenzo, Bodini, Giorgia, Ghisa, Matteo, Gubbiotti, Alessandro, Massimi, Davide, Lorenzon, Greta, Savarino, Edoardo Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263644/
https://www.ncbi.nlm.nih.gov/pubmed/32677808
http://dx.doi.org/10.14309/ctg.0000000000000177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263644/
https://www.ncbi.nlm.nih.gov/pubmed/32677808
http://dx.doi.org/10.14309/ctg.0000000000000177

Ejemplares similares